Sainish Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.84 M
- Revenue Growth -5.77%
- Profit Growth 3.18%
- Ebitda -10.57%
- Net Worth 10.85%
- Total Assets 14.99%
About Sainish Pharma
Sainish Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 November 2008 and has a history of 16 years and three months. Its registered office is in Bathinda, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.84 M.
Varinder Saini and Sunita Rani serve as directors at the Company.
Company Details
-
Location
Bathinda, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232PB2008PTC032387
-
Company No.
032387
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Nov 2008
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Sainish Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varinder Saini
|
Additional Director | 31-May-2023 | Current |
|
Sunita Rani
|
Director | 03-Nov-2008 | Current |
Financial Performance of Sainish Pharma.
Sainish Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.77% decrease. The company also saw a slight improvement in profitability, with a 3.18% increase in profit. The company's net worth Soared by an impressive increase of 10.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sainish Pharma?
In 2023, Sainish Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.84 M
₹0
Charges Breakdown by Lending Institutions
- Oriental Bank Of Commerce : 0.15 Cr
- Others : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Dec 2021 | Others | ₹0.19 M | Open |
| 19 May 2020 | Others | ₹0.15 M | Open |
| 01 Jun 2010 | Oriental Bank Of Commerce | ₹1.50 M | Open |
How Many Employees Work at Sainish Pharma?
Unlock and access historical data on people associated with Sainish Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sainish Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sainish Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
